Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 9Lymphoma, Follicular 4Recurrence 3Lymphoma, B-Cell 3Neoplasms, Plasma Cell 2Burkitt Lymphoma 2Spondylolisthesis 1Spinal Stenosis 1Spinal Cord Neoplasms 1Smoldering Multiple Myeloma 1Neoplasms 1Neoplasm, Residual 1Meningeal Carcinomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphedema 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Intervertebral Disc Displacement 1Intervertebral Disc Degeneration 1Hodgkin Disease 1Failed Back Surgery Syndrome 1Disease Progression 1Disease 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Blood Specimen Collection 9Surveys and Questionnaires 6Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Prednisone 5Mammography 5Colonoscopy 5Biopsy 5Positron Emission Tomography Computed Tomography 4Magnetic Resonance Imaging 4Lenalidomide 4Biopsy, Fine-Needle 4pembrolizumab 3Tomography, X-Ray Computed 3Surgical Procedures, Operative 3Melphalan 3Liquid Biopsy 3Interviews as Topic 3Exercise 3Diagnostic Tests, Routine 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Urination 2Preoperative Exercise 2Positron-Emission Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease × Transplantation, Autologous × Clear all
NCT00950768 2009-08-03

Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients

Azienda Ospedaliera San Giovanni Battista

Phase 3 Completed
298 enrolled
Plasma cell

Disease, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡